ACTINIUM PHARMACEUTICALS news, videos and press releases - Page 5
For more news please use our advanced search feature.
ACTINIUM PHARMACEUTICALS - More news...
ACTINIUM PHARMACEUTICALS - More news...
- Actinium Pharmaceuticals to Present at the Rodman & Renshaw 21st Annual Global Investment Conference
- Actinium Pharmaceuticals, Inc. - ATNM Stock Chart Technical Analysis for 08-21-2019
- Actinium Pharmaceuticals, Inc. - ATNM Stock Chart Technical Analysis for 08-20-2019
- Actinium Pharmaceuticals, Inc. - ATNM Stock Chart Technical Analysis for 07-23-2019
- Actinium Achieves Fifty Percent Enrollment in the Pivotal Phase 3 SIERRA Trial for Iomab-B
- Actinium Highlights Two Presentations at the Health Physics Society Annual Meeting Supporting the Safety Profile of Iomab-B for SIERRA Trial Caregivers
- Actinium Poster Detailing Actinium-225 Labeled Daratumumab Selected in Top Poster Award Competition at 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
- Actinium Presents New Data Demonstrating Effective Lymphodepletion with Lutetium-177 for CAR-T at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
- Actinium's Portfolio of Antibody Radiation-Conjugates to be Highlighted in Two Oral and Two Poster Presentations at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
- Actinium Presents New Pivotal Phase 3 SIERRA Trial Data Showing Rapid Peripheral Blast Reduction and Anti-Leukemic Effect with Single Agent Iomab-B in Older Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia at 2019 ASCO Annual Meeting
- Abstract Highlighting New Data from the Iomab-B Pivotal Phase 3 SIERRA Trial to be Presented at 2019 ASCO Annual Meeting
- Actinium Announces Appointment of Niva Almaula, Ph.D. as Chief Business Officer
- Actinium Pharmaceuticals, Inc. - ATNM Stock Chart Technical Analysis for 04-18-2019
- Actinium Pharmaceuticals, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock and Warrants
- Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants
- Actinium's Leading Clinical, Preclinical, Production and IP Efforts Related to Actinium-225 Highlighted at Preeminent Targeted Alpha Therapy International Symposium
- Actinium Highlights Actimab-A and Venetoclax Synergies Observed in New Studies Presented at AACR
- Actinium Pharmaceuticals, Inc. - ATNM Stock Chart Technical Analysis for 04-01-2019
- Actinium Successfully Completes Second Module of Collaborative Research Program with Astellas; Third Module Initiated
- Actinium Announces Update Including IP and New Data from Novel Combination of Actimab-A and Venetoclax Accepted for Poster Presentation at AACR Annual Meeting
- Actinium Appoints Accomplished FDA and Industry Professional Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs
- Actinium Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Highlights
- Actinium Provides Comprehensive Patent Portfolio Update Including New IP Filings
- Actinium's Late Breaking Oral Presentation at 2019 TCT Meetings Reports New Data on Donor Chimerism Indicating Deep Engraftment in All Iomab-B Treated Patients in the Pivotal Phase 3 SIERRA Trial
- Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy
- Actinium Pharmaceuticals, Inc. - ATNM Stock Chart Technical Analysis for 02-20-2019
- Iomab-B One of Four Late Breaking Oral Presentations to be Presented at the 2019 Transplantation & Cellular Therapy Annual Meeting
- Actinium Provides Patent Portfolio Update for its Iomab-ACT Next-Generation CAR-T Lymphodepletion Program
- Actinium Initiates Novel Phase 1/2 Combination Trial of Actimab-A and Venetoclax
- Actinium Pharmaceuticals to Host Key Opinion Leader Breakfast on Targeted Conditioning for Bone Marrow Transplant and CAR-T on February 7th